HOLON, Israel, April 27, 2016 /PRNewswire/ -- Compugen Ltd.
(NASDAQ: CGEN), a leading predictive drug discovery company, today
announced that the Company will host a conference call at
10:00 AM ET on Tuesday, May 10, 2016, to review the first
quarter 2016 results. The quarterly results will be released on the
Company's website (www.cgen.com) prior to the conference call.
To access the conference call, please dial 1-888-407-2553 from
the US, or +972-3-918-0685 internationally. The conference
call and the accompanying slide presentation will also be available
via webcast through Compugen's website, located at the following
link.
A replay of the conference call and the accompanying slide
presentation will be available approximately two hours after the
completion of the conference call. To access the replay, please
dial 1-888-326-9310 from the US or +972-3-925-5925 internationally.
The replay will be available through May 12,
2016.
About Compugen
Compugen is a leading therapeutic
discovery company utilizing its broadly applicable predictive
discovery infrastructure to identify novel drug targets and develop
first-in-class biologics. The primary focus of the Company's
current pipeline is on immune checkpoint target candidates
discovered by the Company, potentially providing the basis for a
next wave of therapeutics for cancer immunotherapy. Compugen's
business model is based on selectively entering into collaborations
for its novel target candidates and drug product candidates at
various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Israel, with R&D facilities in
Israel and South San Francisco. At
the US facilities, monoclonal antibody therapeutic candidates are
discovered and developed against the Company's novel target
candidates. For additional information, please visit Compugen's
corporate website at http://www.cgen.com/.
Forward-Looking Statement
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of terminology such as
"will," "may," "expects," "anticipates," "believes," and "intends,"
and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that
may cause the actual results, performance or achievements of
Compugen to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Among these risks: Compugen's business
model is substantially dependent on entering into collaboration
agreements with third parties and may not be successful in
generating adequate revenues or commercializing aspects of our
business model, and the development and commercialization of
therapeutic candidates involve many inherent risks, including
failure to progress to clinical trials or, if they progress to or
enter clinical trials, failure to receive regulatory approval.
These and other factors are more fully discussed in the "Risk
Factors" section of Compugen's most recent Annual Report on Form
20-F as filed with the Securities and Exchange Commission as well
as other documents that may be subsequently filed by Compugen from
time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/compugen-first-quarter-2016-conference-call-and-webcast-scheduled-for-tuesday-may-10-2016-at-1000-am-et-300258326.html
SOURCE Compugen Ltd.